ESC: Amarin's Vascepa reduces patients' arterial plaque after 18 months of treatment

Vascepa cut patients' coronary plaque by 17% over baseline in an 18-month imaging study investigating the mechanism of action behind the pill's FDA-approved CV risk benefits, according to late-breaking science presented Saturday at the European Society of Cardiology's virtual annual meeting.